We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Teva to acquire Chinese biogenerics manufacturer.
- Authors
Katsnelson, Alla
- Abstract
The article informs that with follow-on biologics in the U.S. still stuck in regulatory purgatory, Israeli generics giant Teva Pharmaceuticals Industries Ltd. is forging ahead in biogenerics through a Chinese acquisition. By tackling less strictly regulated markets first, Teva could gain more experience in manufacturing biogenerics and profit from those markets directly. In May, 2005 Teva announced informal plans to fully acquire Chinese biogenerics manufacturer Tianjin Hualida Biotechnology Pharmaceutical Co. Formal announcement of the acquisition will be made in the next months.
- Subjects
ISRAEL; MERGERS &; acquisitions; TEVA Pharmaceutical Industries Ltd.; GENERIC drugs; MANUFACTURED products; PHARMACEUTICAL industry
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 7, p765
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0705-765